Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.33
+0.63004.96%
Post-market: 13.330.00000.00%16:38 EDT
Volume:867.89K
Turnover:11.65M
Market Cap:736.41M
PE:-4.83
High:13.85
Open:12.70
Low:12.55
Close:12.70
52wk High:16.93
52wk Low:6.96
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.74
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.81
PE(LYR):-5.51

Loading ...

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18

4D Molecular Therapeutics Grants 35,200 RSUs to Five New Hires Under Inducement Award Plan

Reuters
·
Aug 15

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials

TIPRANKS
·
Aug 14

4D Molecular Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 Net Loss Widens

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 EPS $(1.04) Beats $(1.06) Estimate, Sales $3.781M Beat $3.100M Estimate

Benzinga Earnings
·
Aug 14

4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million

Reuters
·
Aug 14

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire
·
Aug 14

4D Molecular Therapeutics Inc Expected to Post a Loss of $1.02 a Share - Earnings Preview

Reuters
·
Aug 07

4D Molecular Therapeutics CEO David Kirn Disposes of 12,415 Shares Worth $124,987

Reuters
·
Aug 05

4D Molecular Therapeutics Inc : B. Riley Initiates Coverage with Buy Rating; Target Price $37

THOMSON REUTERS
·
Jul 31

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jul 21

4D Molecular Therapeutics Posts Strong 4D-150 Trial Results

TIPRANKS
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 20

4D Molecular Therapeutics Price Target Maintained with a $36.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20